Clinical Research Directory
Browse clinical research sites, groups, and studies.
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Summary
The aim of this study is to assess the efficacy and safety of durvalumab combined with S-1 as adjuvant therapy of resectable Biliary Tract Cancer(BTC) with high risk of recurrence
Official title: A Single-arm, Single-center Study of Durvalumab Combined With S-1 as Adjuvant Therapy for Resectable Biliary Tract Cancer(BTC) With High Risk of Recurrence
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-05-24
Completion Date
2027-12-30
Last Updated
2024-07-08
Healthy Volunteers
No
Conditions
Interventions
Durvalumab combined with S-1
The treatment regimen for this study is as follows: First 8 cycles of adjuvant therapy: Durvalumab 1500mg, (Day 1, IV, Q3W) and S-1 40mg/m2 (Day1-14, BID, Q3W), up to 8 cycles. Maintenance therapy stage(6 cycles):If the patients do not experience disease recurrence or intolerance after first 8 cycles of adjuvant therapy, then, Durvalumab 1500mg, (IV, Q4W), up to 6 cycles
Locations (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, China